Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| CSTB2023NSCQ-MSX0078 | Other Grant/Funding Number | Natural Science Foundation of Chongqing, China General Project | |
| 2024MSXM069 | Other Grant/Funding Number | Joint project of Chongqing Health Commission and Science and Technology Bureau |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this clinical trial is to learn if Gabapentin works to treat flushing/erythema associated with rosacea. It will also learn about the safety of drug Gabapentin. The main questions it aims to answer are:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| minocycline combined with hydroxychloroquine | Experimental |
| |
| gabapentin 300mg bid | Active Comparator |
| |
| gabapentin 300mg tid | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| minocycline combined with hydroxychloroquine | Drug | Patients with rosacea were collected and randomly divided into three groups for treatment, one group was treated with minocycline combined with hydroxychloroquine, one group was treated with gabapentin 300mg Bid, and the other group was treated with gabapentin 300mg tid. Before treatment, 4 weeks after treatment, and 8 weeks after treatment, the patient's condition score was statistically analyzed, and the efficacy and difference of each group were observed |
| Measure | Description | Time Frame |
|---|---|---|
| the score of CEA ( Clinician Erythema Assessment ) | The reduction of the CEA score was compared before treatment, 4 weeks and 8 weeks, 12 weeks after treatment. The CEA score was assessed by a scale, 0 = clear, 1= almost clear, 2 =Mild, 3= Moderate,4= Severe. | 4 weeks, 8 weeks, 12 weeks after treatment |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
â‘ received other treatment within 4 weeks of this treatment; â‘¡ facial flushing caused by other diseases and local irritation; â‘¢ Patients with contraindication to minocycline, hydroxychloroquine, gabapentin and carvedilol; â‘£ Unable to complete follow-up and serum specimen collection; â—‹5 patients were intolerant to minocycline, hydroxychloroquine and carvedilol; â—‹6 Lactation, pregnancy, liver and kidney dysfunction, psychiatric diseases, cardiovascular and cerebrovascular diseases, systemic lupus erythematosus and other systemic diseases.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| First Affiliated Hospital of Chongqing Medical University | Chongqing | 404100 | China |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 34840653 | Result | Del Rosso JQ, Webster G, Weiss JS, Bhatia ND, Gold LS, Kircik L. Nonantibiotic Properties of Tetracyclines in Rosacea and Their Clinical Implications. J Clin Aesthet Dermatol. 2021 Aug;14(8):14-21. Epub 2021 Aug 1. | |
| 39681269 | Result | Ma G, Zhang Y, Gao Q, Yuan X, Zhou Z, Jian D, Zhao Z, Wang B, Li J. Gabapentin improves the flushing of rosacea, but not other rosacea symptoms or quality of life: Results from a multicenter, randomized, double-blind, placebo-controlled pilot study. J Am Acad Dermatol. 2025 Apr;92(4):920-922. doi: 10.1016/j.jaad.2024.12.003. Epub 2024 Dec 15. No abstract available. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| gabapentin 300mg bid | Drug | Patients with rosacea were collected and randomly divided into three groups for treatment, one group was treated with minocycline combined with hydroxychloroquine, one group was treated with gabapentin 300mg Bid, and the other group was treated with gabapentin 300mg tid. Before treatment, 4 weeks after treatment, and 8 weeks after treatment, the patient's condition score was statistically analyzed, and the efficacy and difference of each group were observed |
|
| gabapentin 300mg tid | Drug | Patients with rosacea were collected and randomly divided into three groups for treatment, one group was treated with minocycline combined with hydroxychloroquine, one group was treated with gabapentin 300mg Bid, and the other group was treated with gabapentin 300mg tid. Before treatment, 4 weeks after treatment, and 8 weeks after treatment, the patient's condition score was statistically analyzed, and the efficacy and difference of each group were observed |
|
| 39710117 | Result | Wei J, Wan M, Chen Q, Fu J, Yang L, Ni R, Ge L, Dan Y, Chen X, Kong M, Li L, Chen S, Yang S, Zhang L, Xia A, Tang L, Zhang Y, Zhang M, Song Z, Li J. Gabapentin is an efficacy treatment for facial flushing and erythema of erythematotelangiectatic rosacea: A randomized clinical noninferiority trial. J Am Acad Dermatol. 2025 Apr;92(4):927-930. doi: 10.1016/j.jaad.2024.12.011. Epub 2024 Dec 20. No abstract available. |
| 32360760 | Result | Logger JGM, Olydam JI, Driessen RJB. Use of beta-blockers for rosacea-associated facial erythema and flushing: A systematic review and update on proposed mode of action. J Am Acad Dermatol. 2020 Oct;83(4):1088-1097. doi: 10.1016/j.jaad.2020.04.129. Epub 2020 Apr 29. |
| 32989925 | Result | Husein-ElAhmed H, Steinhoff M. Evaluation of the efficacy of subantimicrobial dose doxycycline in rosacea: a systematic review of clinical trials and meta-analysis. J Dtsch Dermatol Ges. 2021 Jan;19(1):7-17. doi: 10.1111/ddg.14247. Epub 2020 Sep 28. |
| 35929658 | Result | Clanner-Engelshofen BM, Bernhard D, Dargatz S, Flaig MJ, Gieler U, Kinberger M, Klovekorn W, Kuna AC, Lauchli S, Lehmann P, Nast A, Pleyer U, Schaller M, Schofer H, Steinhoff M, Schwennesen T, Werner RN, Zierhut M, Reinholz M. S2k guideline: Rosacea. J Dtsch Dermatol Ges. 2022 Aug;20(8):1147-1165. doi: 10.1111/ddg.14849. Epub 2022 Aug 5. |
| 39136023 | Result | Tu KY, Jung CJ, Shih YH, Chang ALS. Therapeutic strategies focusing on immune dysregulation and neuroinflammation in rosacea. Front Immunol. 2024 Jul 29;15:1403798. doi: 10.3389/fimmu.2024.1403798. eCollection 2024. |
| 35385049 | Result | Barakji YA, Ronnstad ATM, Christensen MO, Zachariae C, Wienholtz NKF, Halling AS, Maul JT, Thomsen SF, Egeberg A, Thyssen JP. Assessment of Frequency of Rosacea Subtypes in Patients With Rosacea: A Systematic Review and Meta-analysis. JAMA Dermatol. 2022 Jun 1;158(6):617-625. doi: 10.1001/jamadermatol.2022.0526. |
| ID | Term |
|---|---|
| D012393 | Rosacea |
| ID | Term |
|---|---|
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D006886 | Hydroxychloroquine |
| D000077206 | Gabapentin |
| C494814 | BID protein, human |
| ID | Term |
|---|---|
| D002738 | Chloroquine |
| D000634 | Aminoquinolines |
| D011804 | Quinolines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
| D000588 | Amines |
| D009930 | Organic Chemicals |
| D005680 | gamma-Aminobutyric Acid |
| D000613 | Aminobutyrates |
| D002087 | Butyrates |
| D000144 | Acids, Acyclic |
| D002264 | Carboxylic Acids |
| D003509 | Cyclohexanecarboxylic Acids |
| D000146 | Acids, Carbocyclic |
| D003510 | Cyclohexanes |
| D003516 | Cycloparaffins |
| D006840 | Hydrocarbons, Alicyclic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D000596 | Amino Acids |
| D000602 | Amino Acids, Peptides, and Proteins |
Not provided
Not provided